Longeveron, Inc.

Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene

A panel of drug developers, investors and advisors discussed the merits of going public in the US through an initial public offering or through a merger with a special purpose acquisition corporation

Initial public offerings may have gotten off to a slow start with only three IPOs in January, but 10 drug developers went public in the US between 3 and 5 February raising a total of $1.9bn, including